Immunoglobulins Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Immunoglobulins Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Immunoglobulin Market


The Immunoglobulin market size was valued at USD 15.05 billion in 2022, and the market is now projected to grow from USD 16.24 billion in 2023 to USD 29.57 billion by 2030, exhibiting a CAGR of 8.9% during the forecast period of 2023-2030.

The COVID-19 Pandemic is the Direct Factor for The Global Market owing to a fall In the Plasma Collection and the Labor Shortage for Fractionation. It is for this reason that the major players found themselves in the difficult position of getting blood plasma for the process of plasma fractionation. As a result, the patient eligibility is being compromised due to lack of plasma, it includes immunoglobulin where shortage exists. He lowered adoption rates thus Immunoglobulin Market growth stagnation connects with it

The growing incidence of primary immunodeficiency diseases has propelled the enlargement of the Immunoglobulin Market share. As demand surges for therapeutic interventions to reinforce immune function, pharmaceutical groups are innovating to fulfill the wishes of sufferers, riding boom in this essential zone of healthcare.

Consumer desire within the immunoglobulin market is tilting towards subcutaneous administration over intravenous delivery. This shift is driven with the aid of factors which includes convenience, reduced treatment burden, and advanced best of lifestyles for sufferers. Pharmaceutical groups are responding with improved focus on growing and advertising and marketing subcutaneous immunoglobulin products to meet this demand.

Comprehensive Analysis of Immunoglobulin Market

The Immunoglobulin market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessment considering the dominant supply and demand forces that impact the pharmacy benefit management industry. These segmentations are methodically segregated by route of administration analysis, by indication analysis, by form analysis and by end-users analysis. The route of administration analysis include, intravenous and subcutaneous. The indication analysis includes primary immunodeficiency, secondary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, immune thrombocytopenic purpura, multifocal motor neuropathy, and others. The form analysis includes, liquid and lyophilized. However, the end-user analysis such as hospitals, clinics, and homecare.

The North America region lead the Immunoglobulin market by benefitting a market size of USD 9.73 billion in 2023 due to introduction of drugs by leading players and the availability of insurance coverage are fueling the market growth in this region during the study period.

The key players within the Immunoglobulin market play a critical function inside the healthcare industry assuring commercial prospectus growth and setting market standards. These gamers encompass, Takeda Pharmaceutical Company Limited (Japan), CSL (U.S.), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), Bio Products Laboratory Ltd. (U.K.), LFB Group (France), Shanghai RAAS Blood Products Co., Ltd. (China), China Biologic Products Holdings, Inc. (China) these market players provide a competative landscape.

In November 2023, Grifols, S.A has the authority of the FDA to achieve expanded purification and filling capacities in North Carolina. This case-in-point hardens the position of Grifols in the biotherapeutics market, supporting them to become a leader in plasma-derived drugs that are scalable and distributed in a wide range.

Segmentation Table
 
Attribute Details

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 9.3% from 2024-2032

Unit Value (USD billion)

Segmentation By Route of Administration

Intravenous

Subcutaneous

By Indication

Primary Immunodeficiency (PI)

Secondary Immunodeficiency (SID)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Guillain Barré Syndrome

Immune Thrombocytopenic Purpura (ITP)

Multifocal Motor Neuropathy (MMN)

Others

By Form

Liquid

Lyophilized

By End-user

Hospitals

Clinics

Homecare

By Geography

North America (By Route of Administration, By Indication, By Form, By End-user, and By Country)

-U.S.

-Canada

Europe (By Route of Administration, By Indication, By Form, By End-user, and By Country/Sub-region)

-U.K.

-Germany

-France

-Italy

-Spain

-Scandinavia

-Rest of Europe

Asia Pacific (By Route of Administration, Bu Indication, By Form, By End-user, and By Country/Sub-region)

-China

-Japan

-India

-Australia

-Southeast Asia

-Rest of Asia Pacific

Latin America (By Route of Administration, By Indication, By Form, By End-user, and By Country/Sub-region)

-Brazil

-Mexico

-Rest of Latin America

Middle East & Africa (By Route of Administration, Bu Indication, By Form, By End-user, and By Country/Sub-region)

-GCC

-South Africa

-Rest of Middle East & Africa